You are here: Geisinger Medical
Laboratories > Test
Catalog
Geisinger Medical Laboratories/Geisinger Proven Diagnostics Test Catalog
TOBRAMYCIN PEAK |
||
ORDERING INFORMATION: |
Geisinger Epic Procedure Code: LAB3168 Geisinger Epic ID: 29560 | |
SPECIMEN COLLECTION |
||
Specimen type: |
Plasma or serum | |
Preferred collection container: |
||
Specimen required: |
2 mL aliquot serum or plasma; minimum 0.2 mL. | |
Special notes: |
The date and time of the last drug dose should be written on request at the time of order. Typically peak level specimens are collected shortly after the dose is given and trough level specimens are collected shortly before the dose is given. Refer to your prescribing pharmacy for specific information on how drug doses are to be administered along with timing of specimen collection. | |
| SPECIMEN PROCESSING |
||
Specimen processing instructions: |
Allow serum to clot. Centrifuge to separate serum or plasma within 2 hours of collection. | |
Transport temperature: |
Refrigerated (preferred) or frozen. | |
Specimen stability: |
Refrigerated: 3 days. Frozen: 1 month, | |
Rejection criteria: |
Stability limits exceeded. | |
TEST DETAILS |
||
Reference interval: |
6 - 10 mcg/mL. | |
Critical values/courtesy alerts: |
> 12 mcg/mL. | |
CPT code(s): |
80200 | |
| Note: The billing party has sole responsibility for CPT coding. Any questions regarding coding should be directed to the payer being billed. The CPT codes provided by GML are based on AMA guidelines and are for informational purposes only. | ||
Test includes: |
Peak tobramycin, tobramycin last dose time, tobramycin last dose date. | |
Methodology: |
Enzyme Immunoassay (EIA) |
|
Synonyms: |
PTOBRA
|
|
Clinical significance: |
Tobramycin is an aminoglycoside antibiotic used in the treatment of gram-negative bacterial infections, especially Pseudomonas, Proteus, Klebsiella, and also Staphyloccocus. Tobramycin is potentially nephrotoxic and ototoxic, and serial monitoring of peak and trough serum levels may provide the clinician with information to maintain safe and therapeutic levels. | |
Doctoral Director(s:) |
Hoi-Ying Elsie Yu, PhD, DABCC Sheng-Ying (Margaret) Lo, PhD, DABCC |
|
| Review Date: | 12/14/2022 | |